Steven D. Targum, MD founded PharmaStar in 2001, now known as UBC Training and Education Group. In the course of his career, Dr. Targum has been a research scientist at the Natonal Institute of Mental Health (NIMH); the Medical Director of a psychiatric hospital in Sarasota, Florida; Chairman of the Department of Psychiatry at Crozer-Chester Medical Center located outside of Philadelphia; and Professor of Psychiatry and Vice-Chairman of the Department of Mental Health Sciences at Hahnemann University School of Medicine in Pennsylvania. He has published over 100 scientific papers and lectured at professional meetings throughout the world. In addition, Dr. Targum owned and directed a large clinical trials practice in Philadelphia where he conducted over 200 pharmaceutical studies across diverse therapeutic areas including major depression, mania, anxiety disorders, schizophrenia, and Alzheimer's disease.

Dr. Targum received his undergraduate degree in Biology from Colgate University and his medical degree from Mount Sinai School of Medicine in New York City.

Graham Emslie obtained his undergraduate degree and M.D. at Aberdeen University in Aberdeen, Scotland in 1974. Dr. Emslie did his internship at Aberdeen Hospitals, Scotland in general medicine and neurosurgery. He did his residency training in general psychiatry at the University of Rochester, NY and child psychiatry at Stanford University, where he also completed a research fellowship.

Dr. Emslie joined the University of Texas Southwestern Faculty in 1981. His departmental activities include providing mentoring to residents and fellows on psychopharmacology research and directing the Child Psychiatry Outpatient Center at Children's Medical Center. He served as the Director of the Child Psychiatry Inpatient Service at Children's Medical Center (1981-1998). Dr. Emslie's clinical expertise is in the area of child and adolescent depression.

Dr. Emslie's research foci are in the areas of conducting efficacy and effectiveness trials with medications and psychotherapy for children and adolescents with depression, anxiety disorders, and attention-deficit disorder. He is also involved with developing and evaluating medication algorithm protocols for children and adolescents with depression.

Dr. Emslie is active in the following professional organizations: American Academy of Child and Adolescent Psychiatry, American Psychiatric Association, Texas Society of Child and Adolescent Psychiatry, Texas Society of Psychiatric Physicians, Society of Biological Psychiatry, and the International Society for Research in Child and Adolescent Psychopathology. He is also on several committees, including the National Institute of Mental Health (NIMH) Interventions Committee, NIMH Child Council Work Group, and the Corporate Contributions and Research Committee for the American Academy of Child and Adolescent Psychiatry. In addition, he serves on the editorial board for the Journal of the American Academy of Child and Adolescent Psychiatry. He is also past President for the Texas Society of Child and Adolescent Psychiatry.

Hubert H. Fernandez, MD, Director, Clinical Trials for Movement Disorders, neurologist and movement disorders specialist, completed residency training at Boston University where he was first exposed to the field of Parkinson’s disease and other movement disorders. He then completed his fellowship training in Movement disorders at Brown University where he later served as Associate Director of the Movement Disorders Program, Director of the Parkinson's Day Program and Neurological Director of the Functional Neurosurgical Program for Movement Disorders, before moving to the University of Florida.

Being an active member of the Parkinson Study Group and the Huntington Study Group, Dr. Fernandez has a strong interest in clinical trials and has initiated and participated in numerous single-center and multi-center trials for the delay and symptomatic treatment of Parkinson’s disease, Huntington’s disease and dystonia. He also has a strong interest and several publications on epidemiology, long-term/nursing syndromes such as psychosis, anxiety, depression, dementia and sleep disturbances. He has authored/co-authored over 65 peer-reviewed articles and 25 books/book chapters on various aspects of movement disorders and currently reviews for 12 medical/scientific journals.

Joseph H. Friedman is a Professor of Clinical Neurosciences at Brown University Medical School, Chief of the section on Parkinson's disease & Movement Disorders, and adjunct professor in the School of Pharmacy at the University of Rhode Island. He is a fellow of the American Academy of Neurology and a member of the American Neurological Association. He is Editor-in-Chief of Rhode Island’s state medical journal and serves on the editorial board of Movement Disorders. His areas of research focus include drug-induced psychosis in Parkinson's disease, effects of atypical antipsychotic drugs on movement disorders, and behavioral abnormalities in Parkinson's Disease.

Dr. Jarema received his M.D. from Pomeranian School of Medicine in Szczecin, Poland in 1970 and received his Ph.D. in 1974. Dr. Jarema practices at the leading national teaching hospital in Poland and lectures often in psychiatry for postgraduate students. He has participated in the management of scientific research programs in clinical psychiatry, psychopharmacology and psychopathology. Dr. Jarema has been a Principal Investigator in many clinical trials and trains often on the use of subjective clinical instruments. Dr. Jarema has published in over 220 scientific publications and journals mainly in the field of schizophrenia-biological aspects in psychiatric patients.

Department of Psychiatry and Human Behavior at the Brown University School of Medicine in Providence, Rhode Island. He is also Executive Chief Psychiatrist at the seven Brown University affiliated hospitals. Dr. Keller received his medical training at Cornell University, and completed a medical internship at Bellevue Medical Center in New York City and a psychiatric residency at Massachusetts General Hospital in Boston.

Dr. Keller's research interests include investigation of nosology and long-term course of psychiatric illnesses, including mood disorders, anxiety disorders and eating disorders, and the effect of treatment (both neuropsychopharmacologic compounds and psychotherapy) on the short-and long-term clinical course of these illnesses in adolescents and adults. He directs multi-institutional randomized clinical trials which investigate the safety and efficacy of antidepressant agents and psychotherapy with children and adolescents with bipolar and unipolar illness, and several multisite studies of the acute, continuation and maintenance treatments of chronic major depression and double depression.

Dr. Keller served as Chairman of the Scientific Advisory Board of the National Depressive and Manic Depressive Association from 1995-1998. He has served on many committees of the National Institute of Mental Health (NIMH), including the NIH Consensus Conference on Mood Disorders and the planning committee for the NIH Consensus Conference on Panic Disorder. Dr. Keller is co-editor of International Journal of Clinical Psychopharmacology, and on the Editorial Boards of Journal of Clinical Psychiatry, Journal of Affective Disorders, and Depression and Anxiety, as well as the International Advisory Board of Acta Psychiatrica Scandinavica. He is a reviewer for 10 other journals. He has over 200 original articles published in peer-reviewed journals, and a total of over 250 chapters, editorials and journal articles. Dr. Keller is the recipient of the 1997 Award for Research in Psychiatry from the American Psychiatric Association for his research on the longitudinal course and neuropsychopharmacology of affective disorders and anxiety disorders. He is the recipient of the 1998 National Alliance for Research on Schizophrenia and Depression (NARSAD) Lieber award for research on the causes, psychopathology, treatment and prevention of depression and bipolar illness that leads to advancing our understanding of affective illness and new treatment approaches. Dr. Keller is also the recipient of the 1998 National Depressive and Manic Depressive Association (NDMDA) Gerald R. Klerman Lifetime Research Award for lifetime research contributions to the diagnosis and treatment of depressive and manic-depressive illness.

Dr. Malloy is Director of Psychology and Co-Director of the Memory Disorders Program at Butler Hospital. He also directs the NIA-funded Brown Dementia Research training program, designed to prepare new independent investigators in translational dementia research. He is a fellow of the American Neuropsychiatric Association and the National Academy of Neuropsychology. Dr. Malloy has published over 80 peer-reviewed articles focusing on dementia and frontal lobe functions, co-authored two recent books on neuropsychiatric disorders, and presents regularly at national meetings. He has consulted to the pharmaceutical industry on design of clinical trials, training of investigators in outcome measurement, and preparation of critical reviews of the literature for regulatory purposes. His current research interests include measurement of executive functions, neuro-imaging of white matter disease, and prediction of conversion to dementia.

Mark H. Rapaport, M.D. is an Associate Professor of Psychiatry in Residence at the University of California, San Diego (UCSD) and a staff psychiatrist in the San Diego Veterans Affairs Health Care System. He serves as the Director of the UCSD Mental Health Outpatient Clinical Research Center and the UCSD site for the NIMH STEP-Bipolar Disorder Program, and is the Co-Director of the UCSD Psychopharmacology Research Program.

Dr. Rapaport is a nationally recognized expert in the area of psychopharmacology. He has been a counselor of the San Diego Psychiatric Society from 1992 - 1995, and served on the Board of Advisors to the San Diego Psychiatric Health Association since 1994. Dr. Rapaport is a fellow of the American Psychiatric Association and was recognized as the "Clinician of the Year" by the San Diego Psychiatric Society in 2000. He was recognized as the Outstanding Teacher of the Year by the UCSD Department of Psychiatry in 2001.

Dr. Rapaport completed his undergraduate medical studies at the University of California, San Diego. Upon completion of his residency and research fellowship in the UCSD Department of Psychiatry, Dr. Rapaport was a Medical Staff Fellow at the National Institute of Mental Health in Bethesda, M.D. From 1989 to 1990, Dr. Rapaport served as Chief of the NIMH Psychopharmacology and Somatic Treatments Program in the Schizophrenia Research Branch, Division of Clinical Research.

An active leader in various psychiatric professional societies, Dr. Rapaport is a frequent lecturer at national and international psychiatric scientific symposia. He developed and co-directs the New Investigators Program at the NCDEU meeting for the National Institute of Mental Health. His research has been widely published in peer-reviewed psychiatric journals and he serves on numerous editorial review boards.

Karl Rickels, M.D. is the Stuart and Emily Mudd Professor of Human Behavior and Professor of Psychiatry, School of Medicine, University of Pennsylvania. He is Chief of the Mood and Anxiety Disorders Section, Department of Psychiatry, and Chief of the Division of Human Behavior and Reproduction, Department of OB/GYN at the Hospital of the University of Pennsylvania. He is a Life Fellow of the American Psychiatric Association and Charter Fellow of the American College of Neuropsychopharmacology (ACNP). Dr. Rickels received his medical training in Germany and completed his psychiatric residency at the Hospital of the University of Pennsylvania.

Dr. Rickels is an internationally recognized expert in psychopharmacology with particular interest in anxiety disorders. He has written and edited seven books and has published more than 550 peer-reviewed publications, book chapters, or reviews. Since 1959, Dr. Rickels and his associates have received continuous peer-reviewed support from the National Institute of Mental Health (NIMH), including a MERIT award. His main areas of academic interest are the psychopathology and treatment of anxiety, panic disorder, depression, PMS and benzodiazepine dependence.

Dr. Rickels has served on advisory committees for the Food and Drug Administration (FDA) and the NIMH. Presently he serves on several editorial boards of psychiatric journals and has served on numerous national scientific committees, including chairing the FDA-OTC Review Committee on over-the-counter daytime and nighttime sedatives and stimulants, being a member of the APA Task Force on benzodiazepine dependence, and more recently serving as section co-editor of the clinical segment of the NIMH/ACNP-sponsored volume entitled: Clinical Evaluation of Psychotropic Drugs: Principles and Guidance.

Moira Rynn, M.D., is co-director of the Child and Adolescent Assessment and Treatment Service, a treatment research program, at the University of Pennsylvania.

Dr. Sajatovic is a researcher, educator and clinician who has devoted herself to the study and treatment of traditionally hard-to treat populations with serious mental illness.

Dr. Sajatovic received her B.D. in biology at Ohio State University and completed medical school at the Medical College of Ohio at Toledo. Dr. Sajatovic completed her residency training in psychiatry at University Hospitals of Cleveland where she was Chief Resident in Research. Following completion of her residency, Dr. Sajatovic was Clinical Director of Inpatient Schizophrenia Research at University Hospitals of Cleveland and later was Associate Chief of Psychiatry and Chief of the Mood Disorders Program at the Cleveland Veterans Affairs Medical Center in Cleveland, Ohio. She has been Chief Clinical Officer of an acute care state-funded facility, NorthCoast Behavioral HealthCare, and currently practices Geropsychiatry at University Hospitals of Cleveland.

Dr. Solomon is a Fellow of the American Psychological Association, the American Association for the Advancement of Science, and a member of the National Academy of Neuropsychology. Dr. Solomon specializes in memory disorders related to Alzheimer’s disease. He has published and presented studies for over 20 years on the diagnosis and treatment of Alzheimer’s Disease. Dr. Solomon has authored five books, contributed chapters to 15 edited volumes, and coauthored and presented over 175 research papers. He is a recipient of a National Research Service Award from the National Institutes of Health. Most recently he developed the "7 Minute Screen", a new tool for testing people for the early signs of Alzheimer's disease and other forms of dementia.

Dr. Walling received his training in Counseling Psychology at the University of Southern California and completed his psychology internship at the University of Texas Medical Branch. Before founding CNS Network he was the Vice President of Clinical Services for Psychiatric Management Resources and formerly an Assistant Professor of Psychiatry and Behavioral Sciences at the University of Texas Medical Branch at Galveston.

Dr. Walling's research interests include the assessment of quality of life in severe mental illness, the role of psychologists in treating the mentally ill, post-traumatic stress disorder following natural disasters, and the heritability of mental illness. His research has been presented at numerous international meetings and has been published in such journals as the American Journal of Psychiatry, Mental Health Services Research, and Psychiatric Services.

Dr. Walling serves as the Principal Investigator for clinical trials with an emphasis on schizophrenia, bipolar disorder and depression. Over the past 12 years, Dr. Walling has conducted numerous phase I through III trials. He has also served as a consultant to pharmaceutical companies for protocol development and has conducted many rater-training programs.